281 related articles for article (PubMed ID: 25755489)
21. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
Hahn D; Hodson EM; Hamiwka LA; Lee VW; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004290. PubMed ID: 31840244
[TBL] [Abstract][Full Text] [Related]
22. Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study.
Sommerer C; Brunet M; Budde K; Millán O; Guirado Perich L; Glander P; Meuer S; Zeier M; Giese T
Br J Clin Pharmacol; 2021 Oct; 87(10):3851-3862. PubMed ID: 33620734
[TBL] [Abstract][Full Text] [Related]
23. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
Montero N; Quero M; Melilli E; Pérez-Sáez MJ; Redondo-Pachón D; Bestard O; Crespo M; Cruzado JM; Pascual J
Transplantation; 2019 Oct; 103(10):2031-2056. PubMed ID: 31343574
[TBL] [Abstract][Full Text] [Related]
24. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
25. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression.
Cillo U; Bechstein WO; Berlakovich G; Dutkowski P; Lehner F; Nadalin S; Saliba F; Schlitt HJ; Pratschke J
Transplant Rev (Orlando); 2018 Jul; 32(3):142-150. PubMed ID: 29709248
[TBL] [Abstract][Full Text] [Related]
26. Limitations of current liver transplant immunosuppressive regimens: renal considerations.
Zhang W; Fung J
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):27-32. PubMed ID: 28119255
[TBL] [Abstract][Full Text] [Related]
27. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(4):1-56. PubMed ID: 23074407
[TBL] [Abstract][Full Text] [Related]
28. Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation.
Kamar N; Del Bello A; Belliere J; Rostaing L
Transpl Int; 2015 Aug; 28(8):928-37. PubMed ID: 25557802
[TBL] [Abstract][Full Text] [Related]
29. Current trends in immunosuppressive therapies for renal transplant recipients.
Lee RA; Gabardi S
Am J Health Syst Pharm; 2012 Nov; 69(22):1961-75. PubMed ID: 23135563
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppression Minimization and Avoidance Protocols: When Less Is Not More.
Prashar R; Venkat KK
Adv Chronic Kidney Dis; 2016 Sep; 23(5):295-300. PubMed ID: 27742383
[TBL] [Abstract][Full Text] [Related]
31. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress.
Grinyó JM; Cruzado JM
Am J Transplant; 2009 Nov; 9(11):2447-52. PubMed ID: 19775321
[TBL] [Abstract][Full Text] [Related]
33. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.
Moore J; Middleton L; Cockwell P; Adu D; Ball S; Little MA; Ready A; Wheatley K; Borrows R
Transplantation; 2009 Feb; 87(4):591-605. PubMed ID: 19307799
[TBL] [Abstract][Full Text] [Related]
35. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview.
Höcker B; Tönshoff B
Paediatr Drugs; 2009; 11(6):381-96. PubMed ID: 19877724
[TBL] [Abstract][Full Text] [Related]
36. From immunosuppression to tolerance.
Adams DH; Sanchez-Fueyo A; Samuel D
J Hepatol; 2015 Apr; 62(1 Suppl):S170-85. PubMed ID: 25920086
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive therapy after kidney transplantation: current and new strategies.
Metalidis C; Kuypers D
Minerva Urol Nefrol; 2011 Mar; 63(1):1-19. PubMed ID: 21336242
[TBL] [Abstract][Full Text] [Related]
38. Liver transplantation. The pediatric challenge.
McDiarmid SV
Clin Liver Dis; 2000 Nov; 4(4):879-927. PubMed ID: 11232362
[TBL] [Abstract][Full Text] [Related]
39. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
40. Immunosuppression, Compliance, and Tolerance After Orthotopic Liver Transplantation: State of the Art.
Zorzetti N; Lauro A; Khouzam S; Marino IR
Exp Clin Transplant; 2022 Mar; 20(Suppl 1):3-9. PubMed ID: 35384800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
